tradingkey.logo

Compass Pathways Successfully Achieves Primary Endpoint In Second Phase 3 Trial Evaluating Comp360 Psilocybin

ReutersFeb 17, 2026 11:43 AM

- Compass Pathways PLC CMPS.O:

  • COMPASS PATHWAYS SUCCESSFULLY ACHIEVES PRIMARY ENDPOINT IN SECOND PHASE 3 TRIAL EVALUATING COMP360 PSILOCYBIN FOR TREATMENT-RESISTANT DEPRESSION

  • COMPASS PATHWAYS PLC - COMP360 SHOWS WELL-TOLERATED AND SAFE PROFILE

  • COMPASS PATHWAYS PLC - REQUESTS FDA MEETING FOR ROLLING SUBMISSION

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI